CN1100039C - New compound and its derivatives and their use - Google Patents
New compound and its derivatives and their use Download PDFInfo
- Publication number
- CN1100039C CN1100039C CN 97111758 CN97111758A CN1100039C CN 1100039 C CN1100039 C CN 1100039C CN 97111758 CN97111758 CN 97111758 CN 97111758 A CN97111758 A CN 97111758A CN 1100039 C CN1100039 C CN 1100039C
- Authority
- CN
- China
- Prior art keywords
- compound
- safflower
- present
- medicine
- novel compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a novel compound extracted from safflower and a derivant thereof. The novel compound extracted from safflower has a general formula with a chemical structure of a formula [1] and the activity of the antagonistic effect of calcium ions. In addition, the present invention also relates to the applications of the novel compound extracted from safflower and the derivant thereof on an aspect for preparing medicine, particularly to the applications on an aspect for preparing medicine for treating cardiovascular diseases.
Description
A kind of compound that the present invention relates to extract from safflower the invention still further relates to the purposes of this compound aspect the preparation medicine, the particularly purposes aspect the medicine of preparation treatment cardiovascular disorder.
Safflower is the dried floral of composite family (Compositae) plant Carthamus tinctorius, has the promoting blood circulation to restore menstrual flow effect, is widely used for gynaecopathia and cardiopathic treatment clinically.According to the record of modern Clinical Application and Chinese medicine book on Chinese herbal medicine usage, we have selected neonatal rat myocardial cell to cultivate is the pharmacologically active index, and the effective constituent of safflower has been carried out detailed tracking separation and successfully obtained its effective constituent.Six kinds of new compounds are arranged in these compositions, and 15 kinds of isolated compound from safflower first comprising will inventing described compound, and have been found that this compound has powerful calcium antagonism activity, thereby have been accomplished the present invention.
One of order of the present invention ground provides the compound of a kind of general formula for (1):
Wherein R can be H-CH
3-or
Preferred R is H, and Glc is a glucosyl group.
Two of purpose of the present invention provides the purposes of compound aspect the preparation medicine that a kind of general formula is (1).
It is the purposes of the compound of (1) at preparation cerebrocrast and treating cardiovascular disease prescription face that three of purpose of the present invention provides a kind of general formula.
According to the present invention, preferred R is the effective constituent of formula (1) compound of H as disease treatment, can become medicine to it and/or excipient combined preparation, and this drug regimen has the antagonistic action of calcium ion, can be used for the treatment of cardiovascular disorder.
In order to set forth the present invention better, be exemplified below, but this example is not used for scope of the present invention is limited.
The extraction of embodiment 1 formula (1) compound with separate
1) extracts flos carthami with 50% ethanolic soln, reclaim the aqueous solution that obtains this extract behind the ethanol.
2) behind the aqueous solution that the ethyl acetate extraction safflower extracts, adopt macroporous resin and glucosan gel LH-20 chromatography method to make with extra care with the eluent of 50% second alcohol and water respectively its water-soluble portion, obtain the formula that R is H (1) compound, claim safflower alkali B again.The physical and chemical parameter of this compound is: molecular composition: C
27H
29NO
13Molecular weight: 575; High resolution mass spectrum hrfabms:m/z598.1544[M+Na]
+(calcd 598.1537); Mass spectrum hrfabms:m/z598[M+Na]
+, 576[M+1]
+, 414; Infrared spectra ir (KBr): υ max3431cm
-1, 1636 cm
-1UV spectrum uv: λ max (MeOH) nm (log ε): 250 (3.38), 220 (3.61); [α]
25 D-297 (c=0.1, MeOH); Proton nmr spectra
1H-nmr (in DMSO-d
6): δ 7.35 (1H, d, 15.7, H-8), 7.67 (1H, d, 15.7, H-9), 7.55 (2H, d, 8.6, H-11,15), 6.84 (2H, d, 8.6, H-12,14), 6.25 (1H, d, 2.1, H-17), 5.0～3 0 (suger ' s protons, and H-18,19,20,21), 5.70 (1H, 4-OH), 10.05 (1H, 13-OH), 11.30 (1H, 16-OH), 18.01 (1H, 5-OH); Mr carbon spectrum
13C-nmr (in DMSO-d
6): δ 185.7 (s, C-1), 114.7 (s, C-2), 141.2 (s, C-3), 77.9 (s, C-4), 196.0 (s, C-5), 109.4 (s, C-6), 180.6 (s, C-7), 119.0 (d, C-8), 140.9 (d, C-9), 126.4 (s, C-10), 130.3 (d, C-11,15), 115.7 (d, C-12,14), 160.1 (s, C-13), 138.1 (s, C-16), 101.3 (d, C-17), 74.1 (d, C-18), 78.5 (d, C-19), 70.0 (d, C-20), 63.2 (t, C-21), 84.2 (d, C-1 '), 691 (d, C-2 '), 78.2 (d, C-3 '), 70.0 (d, C-4 '), 78.8 (d, C-5 '), 60.8 (t, C-6 ')
Claims (4)
1. new compound, its chemical general formula is:
Wherein R is H.
2. the compound of claim 1 is used to prepare the purposes of medicine.
3. according to the purposes described in the claim 2, medicine wherein is a cerebrocrast.
4. according to the purposes described in the claim 2, medicine wherein is the cardiovascular medicine of treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97111758 CN1100039C (en) | 1997-05-08 | 1997-05-08 | New compound and its derivatives and their use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 97111758 CN1100039C (en) | 1997-05-08 | 1997-05-08 | New compound and its derivatives and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1199044A CN1199044A (en) | 1998-11-18 |
| CN1100039C true CN1100039C (en) | 2003-01-29 |
Family
ID=5171850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 97111758 Expired - Fee Related CN1100039C (en) | 1997-05-08 | 1997-05-08 | New compound and its derivatives and their use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1100039C (en) |
-
1997
- 1997-05-08 CN CN 97111758 patent/CN1100039C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1199044A (en) | 1998-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5674900A (en) | Terpenoid-type quinones for treatment of diabetes | |
| EP3412679A1 (en) | Baicalin magnesium, preparation method thereof and application of same | |
| WO2003080634A1 (en) | Novel glucopyranoside and a process of isolation thereof from pterocarpus marsupium pharmaceutical composition containing the same and use thereof | |
| US6777392B2 (en) | 8-(C-β-D-glucopyranosyl)-7, 3', 4'-trihydroxyflavone, process of isolation thereof, pharmaceutical composition and method for the treatment of diabetes | |
| CN103665082B (en) | Hemsleya cucurbitane tetracyclic triterpenoid compound, pharmaceutical compositions containing same and application of compound and pharmaceutical composition | |
| Hou et al. | Tremorgenic toxins from penicillia. II. A new tremorgenie toxin, tremortin B, from Penicillium palitans | |
| CN104910240A (en) | Bougainvillea glabra triterpenoid saponin, hpyerglycemic drugs with triterpenoid saponin as active component and preparation method and application thereof | |
| CN106243120B (en) | The preparation of Sophora alopecuroide flavones Stilbene class extract and its application in cosmetics | |
| CN103626824B (en) | Hemsleya amabilis cucurbitane tetracyclic triterpene compound, pharmaceutical composition comprising compound and application of pharmaceutical composition and compound | |
| CN104761596A (en) | Method for preparing anthocyanin standard substance | |
| D'Agostino et al. | Flavonoid glycosides of Alchemilla vulgaris L. | |
| Klohs et al. | Alkaloids of Rauwolfia serpentina Benth. II. 1 The Isolation of Naturally Occurring Py-tetrahydroserpentine (Ajmalicine) and a Contribution Toward its Structure | |
| CN102796112A (en) | Prenylflavonoid compound and application thereof in preparation of pancrelipase inhibitor | |
| CN1100039C (en) | New compound and its derivatives and their use | |
| CN101817827A (en) | Method for preparing sesamin from sesame | |
| CN1075498C (en) | New compound and its derivatives and their use | |
| CN101205249A (en) | Method for preparing laxogenin by smilax scobinicaulis plants | |
| US20040044067A1 (en) | Toralactone and its derivation and the use of decreasing blood-fat and losing weight | |
| CN102295678B (en) | Purpose of triterpenoid-saponin compound extracted form anemone taipaiensis | |
| EP1963350A1 (en) | Biologically active compounds | |
| CN104151375B (en) | A kind of the Kunlun snow chrysanthemum phenolic glycoside compound and its production and use | |
| CN104098624B (en) | The preparations and applicatio of a kind of mating type the Kunlun snow chrysanthemum phenyl styryl ketone glycoside compounds | |
| CN102603833A (en) | Extraction and separation process of apigenin-7-O-beta-D-glucopyranside from garden balsam stem | |
| CN107082780A (en) | A kind of alkaloid with the parallel isoquinoline structure of pyrroles and preparation method and application | |
| CN100586947C (en) | Compound with antineoplastic activity, production method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |